OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
PETV.PK55

PetVivo Holdings Inc

Medical Equipment, Supplies & DistributionVerified

PetVivo operates with a liquidity position that is below the industry median, as evidenced by a current ratio of 0.74, indicating that the company's current liabilities exceed its current assets. The company's liquidity_fpt score is also below the industry median, with a negative operating cash flow of -$7.42 million and a free cash flow of -$2.65 million, both of which are significant red flags for short-term solvency. Profitability metrics are deeply negative, with a return on equity of -3.86 and a return on assets of -0.85, both of which are far below the industry median for Medical Equipment, Supplies & Distribution. The company reported a net loss of $2.65 million and an operating loss of $2.65 million in the latest period. These figures suggest that the company is not currently generating returns that justify its cost of capital. The company's revenue is concentrated in a single business model, with no disclosed geographic diversification in the input data. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in the veterinary healthcare space. The absence of segment data in the input data prevents a more granular analysis of revenue concentration. Looking ahead, the company's revenue outlook is negative, with no disclosed growth trajectory in the input data. The latest financials show a decline in operating performance, and the company has not provided forward-looking guidance that would suggest a reversal of this trend. The absence of a disclosed capex plan or R&D investment also limits visibility into future growth drivers. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company has a debt-to-equity ratio of 0.25, which is relatively low, but its negative operating cash flow and free cash flow raise concerns about its ability to service debt. The risk assessment also notes that net cash is negative after subtracting total debt, which could pressure the company to raise additional capital in the near term. Recent events include the filing of a 10-K for the fiscal year ending December 31, 2023, which disclosed the company's financial challenges, including a net loss and negative cash flows. No recent earnings call transcripts or press releases were provided in the input data, limiting visibility into management's strategic response to these challenges.

30-day price · PETV.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyPetVivo Holdings Inc
TickerPETV.PK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. PetVivo Holdings Inc is a provider of pet health and wellness products, including prescription medications, supplements, and diagnostic tools, primarily distributed through veterinary clinics and online channels.

Classification. PetVivo is classified under the Healthcare sector, specifically in the Medical Equipment, Supplies & Distribution industry, with a high confidence level of 0.92 based on verified market data.

PetVivo operates with a liquidity position that is below the industry median, as evidenced by a current ratio of 0.74, indicating that the company's current liabilities exceed its current assets. The company's liquidity_fpt score is also below the industry median, with a negative operating cash flow of -$7.42 million and a free cash flow of -$2.65 million, both of which are significant red flags for short-term solvency. Profitability metrics are deeply negative, with a return on equity of -3.86 and a return on assets of -0.85, both of which are far below the industry median for Medical Equipment, Supplies & Distribution. The company reported a net loss of $2.65 million and an operating loss of $2.65 million in the latest period. These figures suggest that the company is not currently generating returns that justify its cost of capital. The company's revenue is concentrated in a single business model, with no disclosed geographic diversification in the input data. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in the veterinary healthcare space. The absence of segment data in the input data prevents a more granular analysis of revenue concentration. Looking ahead, the company's revenue outlook is negative, with no disclosed growth trajectory in the input data. The latest financials show a decline in operating performance, and the company has not provided forward-looking guidance that would suggest a reversal of this trend. The absence of a disclosed capex plan or R&D investment also limits visibility into future growth drivers. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company has a debt-to-equity ratio of 0.25, which is relatively low, but its negative operating cash flow and free cash flow raise concerns about its ability to service debt. The risk assessment also notes that net cash is negative after subtracting total debt, which could pressure the company to raise additional capital in the near term. Recent events include the filing of a 10-K for the fiscal year ending December 31, 2023, which disclosed the company's financial challenges, including a net loss and negative cash flows. No recent earnings call transcripts or press releases were provided in the input data, limiting visibility into management's strategic response to these challenges.
Key takeaways
  • PetVivo is operating at a net loss with negative cash flows, indicating a lack of profitability and liquidity.
  • The company's return on equity and return on assets are significantly below industry medians, signaling poor capital efficiency.
  • Revenue is not diversified by segment or geography, increasing exposure to market-specific risks.
  • The company's liquidity position is weak, with a current ratio below 1 and negative operating cash flow.
  • No forward-looking guidance or growth drivers are disclosed, limiting visibility into future performance.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$48.3k
Gross profit$225.4k
Operating income-$2.6M
Net income-$2.7M
R&D
SG&A
D&A
SBC
Operating cash flow-$7.4M
CapEx-$309.1k
Free cash flow-$2.6M
Total assets$3.1M
Total liabilities$2.4M
Total equity$686.0k
Cash & equivalents$87.4k
Long-term debt$170.7k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$12.6k-$1.6M-$3.5M-$3.6M
FY-3$115.6k-$5.0M-$5.0M-$5.1M
FY-2$917.2k-$8.7M-$8.7M-$9.0M
FY-1$968.7k-$10.9M-$11.0M-$11.1M
FY0$1.1M-$8.0M-$8.4M-$8.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$835.2k-$897.0k$23.6k
FY-3$7.4M$6.0M$6.1M
FY-2$2.4M$725.0k$475.3k
FY-1$3.1M$686.0k$87.4k
FY0$9.3M$4.2M$227.7k
PeriodOCFCapExFCFSBC
FY-4-$767.2k-$160.2k-$3.6M
FY-3-$4.2M-$183.2k-$5.1M
FY-2-$6.8M-$423.9k-$9.0M
FY-1-$7.4M-$309.1k-$11.1M
FY0-$5.3M-$563.4k-$8.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$48.3k-$2.6M-$2.7M-$2.6M
FQ-6$123.8k-$2.0M-$2.0M-$2.0M
FQ-5$200.7k-$2.2M-$2.2M-$2.1M
FQ-4$583.3k-$1.8M-$1.8M-$1.7M
FQ-3$224.8k-$2.0M-$2.4M-$2.9M
FQ-2$297.5k-$1.8M-$2.3M-$2.2M
FQ-1$303.3k-$2.1M-$3.0M-$3.0M
FQ0$286.1k-$2.2M-$2.2M-$2.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$3.1M$686.0k$87.4k
FQ-6$2.9M$829.5k$12.4k
FQ-5$3.2M$409.2k$126.2k
FQ-4$3.1M-$694.8k$28.9k
FQ-3$9.3M$4.2M$227.7k
FQ-2$6.9M$3.7M$3.3M
FQ-1$5.3M$4.2M$767.9k
FQ0$4.4M$3.4M$18.2k
PeriodOCFCapExFCFSBC
FQ-7-$7.4M-$309.1k-$2.6M
FQ-6-$1.5M-$15.2k-$2.0M
FQ-5-$3.1M-$18.6k-$2.1M
FQ-4-$4.1M-$42.2k-$1.7M
FQ-3-$5.3M-$563.4k-$2.9M
FQ-2-$1.6M$0.00-$2.2M
FQ-1-$3.8M-$12.9k-$3.0M
FQ0-$5.3M-$7.7k-$2.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$686.0k
Net cash-$83.3k
Current ratio0.7
Debt/Equity0.2
ROA-85.1%
ROE-3.9%
Cash conversion2.8%
CapEx/Revenue-6.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricPETV.PKActivity
Op margin-5487.4%3.9% medp25 -31.3% · p75 14.4%bottom quartile
Net margin-5491.4%2.4% medp25 -30.5% · p75 11.1%bottom quartile
Gross margin466.9%46.7% medp25 28.2% · p75 63.1%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-640.4%-4.8% medp25 -11.6% · p75 -2.4%bottom quartile
Debt / equity25.0%17.9% medp25 2.7% · p75 52.2%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 07:01 UTC#94a61816
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 23:06 UTCJob: 5126b36c